NICE is moving closer to wider NHS use of hybrid closed-loop technology for people living with type 1 diabetes, with draft guidance published in June 2026 pointing to a new approach to insulin delivery that could improve day-to-day management for patients and reduce the burden of constant glucose monitoring and dose adjustments. The development adds to a growing list of diabetes technology recommendations from the health technology assessor, which has increasingly focused on devices that can support better control while easing pressure on patients and services. ([nice.org.uk](https://www.nice.org.uk/guidance/gid-ng10450/documents/supporting-documentation?utm_source=openai))
What the draft guidance says
The draft documentation for NICE’s updated approach to hybrid closed-loop systems was published in June 2026, signalling that the organisation is actively reviewing how this technology should be used in routine care. While the published materials available do not provide final guidance in the same way as a completed recommendation, they show NICE continuing to assess digital and device-based diabetes treatments as part of its wider guidance programme. ([nice.org.uk](https://www.nice.org.uk/guidance/gid-ng10450/documents/supporting-documentation?utm_source=openai))
That matters for NHS services because NICE’s recent news output has repeatedly shown how quickly a positive recommendation can translate into access decisions across England, including in other areas of medicine such as cancer, neonatal infection and liver preservation technology. The same pattern suggests that diabetes care remains a priority area for technology-led change. ([nice.org.uk](https://www.nice.org.uk/news/articles))
A wider shift toward device-led care
The latest diabetes-related work sits alongside a broader NHS and NICE push to speed up access to health technologies and medicines. NICE has already described new national access arrangements designed to deliver faster and fairer use of healthtech, and it has also launched an aligned approval pathway with the MHRA to bring new medicines to patients more quickly. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme?utm_source=openai))
For people with type 1 diabetes, hybrid closed-loop systems are part of that wider shift: tools that combine monitoring and insulin delivery in a way that may reduce manual decision-making and support more stable management. NICE’s recent activity shows that the organisation is treating such technologies as increasingly central to modern care, rather than optional add-ons. ([nice.org.uk](https://www.nice.org.uk/guidance/gid-ng10450/documents/supporting-documentation?utm_source=openai))
Why this matters for patients and the NHS
Although the current published materials are limited to draft and supporting documentation, the direction is clear. NICE is continuing to assess technologies that can change clinical pathways, and diabetes care is among the areas likely to benefit most when those assessments lead to routine NHS use. If the final guidance follows the same direction as the draft, the result could be more consistent access and less variation in care for eligible patients. ([nice.org.uk](https://www.nice.org.uk/guidance/gid-ng10450/documents/supporting-documentation?utm_source=openai))
For now, the key takeaway is that NICE’s June 2026 diabetes technology work is part of a broader attempt to make NHS care more responsive to innovation. In a system under pressure, that makes every new recommendation significant not just for one condition, but for the way care is delivered more widely. ([nice.org.uk](https://www.nice.org.uk/news/articles))
